You are here: Home >Archive for the ‘Anti-Acidity’ Category

ABILIFY (Aripiprazole) In Treatment Of Depression Disorder

ABILIFY (Aripiprazole) drug was developed by two companies: Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company. In 2004 Abilify  medicine was approved in for treating schizophrenia disease and in 2008 it was ratified as medicine for bipolar disorder.
It has been known today that the U.S. Food and Drug Administration (FDA) [...]

Tags: , , , ,

  • Digg
  • Del.icio.us
  • StumbleUpon
  • Reddit
  • Twitter
  • RSS

Abilify (Aripiprazole) Medicine For Bipolar Disorder Is Allowed To Be Marketing

Abilify drug was generally approved in 2004 for treating schizophrenia disease and this medicine was supposed to be used in treating bipolar disorder. Indeed, on April 8, 2008, the European Commission allowed Abilify medication (Aripiprazole) to be marketed for patients with Bipolar I Disorder.
Such kind of disease as Bipolar I Disorder contains [...]

Tags: , , ,

  • Digg
  • Del.icio.us
  • StumbleUpon
  • Reddit
  • Twitter
  • RSS

Oral Solution Formulation of Abilify (Aripiprazole) Is Ratified

Abilify antipsychotic medicine was introduced in 2002 as the first and only dopamine partial agonist. It is generally prescribed for the treatment of schizophrenia disease and acute manic and mixed episodes associated with bipolar disorder.
It has been known today that the US Food and Drug Administration (FDA) approved an oral [...]

Tags: , ,

  • Digg
  • Del.icio.us
  • StumbleUpon
  • Reddit
  • Twitter
  • RSS

FDA Granted A Priority Review To Abilify(R) (Aripiprazole) Supplemental New Drug Application

Abilify (Aripiprazole) is considered to be an effective antipsychotic medication for treating schizophrenia disease and Bipolar I Disorder. The drug is developed by two partnered companies: Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company.
They announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) [...]

Tags: , , ,

  • Digg
  • Del.icio.us
  • StumbleUpon
  • Reddit
  • Twitter
  • RSS

Enlarged Indications Of ABILIFY(R) (Aripiprazole) Use

Taro Iwamoto, Ph.D., Chief Executive Officer, President and Chief Operating Officer, Otsuka Pharmaceutical Development and Commercialization, Inc. stated that they are very pleased to receive expanded indications on the use of Abilify (Aripiprazole) in pediatric patients (aged 10-17) and adolescents.
In fact, The FDA first approved ABILIFY antipsychotic medicine for the treatment of [...]

Tags: , ,

  • Digg
  • Del.icio.us
  • StumbleUpon
  • Reddit
  • Twitter
  • RSS

NEXIUM (Esomeprazole) Drug is Effective in Patients With Zollinger-Ellison Syndrome

Zollinger-Ellison syndrome (ZES) is a rare disease, affecting fewer than three out of every million Americans (less than 1,000 people) but it is a serious chronic condition characterized by the development of a tumor or tumors. ZES is chronic, difficult to treat, and may be life-threatening. The symptoms of ZES may [...]

Tags: , , ,

  • Digg
  • Del.icio.us
  • StumbleUpon
  • Reddit
  • Twitter
  • RSS

NEXIUM (Esomeprazole) Medication Lessens Gastric Ulcers In Case Of Taking Long-Term NSAIDs

Nonsteroidal anti-inflammatory drugs (NSAIDs) are considered to be a group of pain relief medications involving traditional, non-selective drugs, such as aspirin, ibuprofen and naproxen, and newer COX-2- selective agents. Actually non-selective NSAIDs enlarge the risk of gastric ulcers, especially in older patients who have a history of gastric ulcers or who [...]

Tags: , , , , ,

  • Digg
  • Del.icio.us
  • StumbleUpon
  • Reddit
  • Twitter
  • RSS
 Page 1 of 3  1  2  3 »